Skip to main content
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1989 Mar 1;169(3):881–891. doi: 10.1084/jem.169.3.881

Amastigotes of Trypanosoma cruzi escape destruction by the terminal complement components

PMCID: PMC2189257  PMID: 2494292

Abstract

We studied the effect of complement on two life cycle stages of the protozoan parasite Trypanosoma cruzi: epimastigotes, found in the insect vector, and amastigotes, found in the mammalian host. We found that while both stages activate vigorously the alternative pathway, only epimastigotes are destroyed. The amounts of C3 and C5b-7 deposited on the amastigotes were similar to those bound to the much larger epimastigotes. Binding of C9 to amastigotes was four to six times less than binding to epimastigotes, resulting in a lower C9/C5b-7 ratio. Although a fairly large amount of C9 bound stably to amastigotes, no functional channels were formed as measured by release of incorporated 86Rb. The bound C9 had the characteristic properties of poly-C9, that is, it expressed a neo-antigen unique to poly-C9, and migrated in SDS- PAGE with an apparent Mr greater than 10(5). The poly-C9 was removed from the surface of amastigotes by treatment with trypsin, indicating that it was not inserted in the lipid bilayer. Modification of amastigote surface by pronase treatment rendered the parasites susceptible to complement attack. These results suggest that amastigotes have a surface protein that binds to the C5b-9 complex and inhibits membrane insertion, thus protecting the parasites from complement-mediated lysis.

Full Text

The Full Text of this article is available as a PDF (740.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andrews N. W., Einstein M., Nussenzweig V. Presence of antibodies to the major surface glycoprotein of Trypanosoma cruzi amastigotes in sera from Chagasic patients. Am J Trop Med Hyg. 1989 Jan;40(1):46–49. doi: 10.4269/ajtmh.1989.40.46. [DOI] [PubMed] [Google Scholar]
  2. Andrews N. W., Hong K. S., Robbins E. S., Nussenzweig V. Stage-specific surface antigens expressed during the morphogenesis of vertebrate forms of Trypanosoma cruzi. Exp Parasitol. 1987 Dec;64(3):474–484. doi: 10.1016/0014-4894(87)90062-2. [DOI] [PubMed] [Google Scholar]
  3. Biesecker G., Müller-Eberhard H. J. The ninth component of human complement: purification and physicochemical characterization. J Immunol. 1980 Mar;124(3):1291–1296. [PubMed] [Google Scholar]
  4. Cooper N. R., Müller-Eberhard H. J. The reaction mechanism of human C5 in immune hemolysis. J Exp Med. 1970 Oct 1;132(4):775–793. doi: 10.1084/jem.132.4.775. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Falk R. J., Dalmasso A. P., Kim Y., Tsai C. H., Scheinman J. I., Gewurz H., Michael A. F. Neoantigen of the polymerized ninth component of complement. Characterization of a monoclonal antibody and immunohistochemical localization in renal disease. J Clin Invest. 1983 Aug;72(2):560–573. doi: 10.1172/JCI111004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Harriman G. R., Podack E. R., Braude A. I., Corbeil L. C., Esser A. F., Curd J. G. Activation of complement by serum-resistant Neisseria gonorrhoeae. Assembly of the membrane attack complex without subsequent cell death. J Exp Med. 1982 Oct 1;156(4):1235–1249. doi: 10.1084/jem.156.4.1235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Joiner K. A., Schmetz M. A., Sanders M. E., Murray T. G., Hammer C. H., Dourmashkin R., Frank M. M. Multimeric complement component C9 is necessary for killing of Escherichia coli J5 by terminal attack complex C5b-9. Proc Natl Acad Sci U S A. 1985 Jul;82(14):4808–4812. doi: 10.1073/pnas.82.14.4808. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Joiner K. A., Warren K. A., Brown E. J., Swanson J., Frank M. M. Studies on the mechanism of bacterial resistance to complement-mediated killing. IV. C5b-9 forms high molecular weight complexes with bacterial outer membrane constituents on serum-resistant but not on serum-sensitive Neisseria gonorrhoeae. J Immunol. 1983 Sep;131(3):1443–1451. [PubMed] [Google Scholar]
  9. Joiner K., Hieny S., Kirchhoff L. V., Sher A. gp72, the 72 kilodalton glycoprotein, is the membrane acceptor site for C3 on Trypanosoma cruzi epimastigotes. J Exp Med. 1985 May 1;161(5):1196–1212. doi: 10.1084/jem.161.5.1196. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Joiner K., Sher A., Gaither T., Hammer C. Evasion of alternative complement pathway by Trypanosoma cruzi results from inefficient binding of factor B. Proc Natl Acad Sci U S A. 1986 Sep;83(17):6593–6597. doi: 10.1073/pnas.83.17.6593. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kierszenbaum F., Lima M. F. Susceptibility of insect-borne, metacyclic forms of Trypanosoma cruzi to antibody-mediated mechanisms of destruction. Am J Trop Med Hyg. 1983 Nov;32(6):1236–1241. doi: 10.4269/ajtmh.1983.32.1236. [DOI] [PubMed] [Google Scholar]
  12. Kipnis T. L., David J. R., Alper C. A., Sher A., da Silva W. D. Enzymatic treatment transforms trypomastigotes of Trypanosoma cruzi into activators of alternative complement pathway and potentiates their uptake by macrophages. Proc Natl Acad Sci U S A. 1981 Jan;78(1):602–605. doi: 10.1073/pnas.78.1.602. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kipnis T. L., Tambourgi D. V., Sucupira M., Dias-da-Silva W. Effect of Trypanosoma cruzi membrane components on the formation of the classical pathway C3 convertase. Braz J Med Biol Res. 1986;19(2):271–278. [PubMed] [Google Scholar]
  14. Ley V., Andrews N. W., Robbins E. S., Nussenzweig V. Amastigotes of Trypanosoma cruzi sustain an infective cycle in mammalian cells. J Exp Med. 1988 Aug 1;168(2):649–659. doi: 10.1084/jem.168.2.649. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Müller-Eberhard H. J. The membrane attack complex of complement. Annu Rev Immunol. 1986;4:503–528. doi: 10.1146/annurev.iy.04.040186.002443. [DOI] [PubMed] [Google Scholar]
  16. Nelson R. A., Jr, Jensen J., Gigli I., Tamura N. Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea-pig serum. Immunochemistry. 1966 Mar;3(2):111–135. doi: 10.1016/0019-2791(66)90292-8. [DOI] [PubMed] [Google Scholar]
  17. Nogueira N., Bianco C., Cohn Z. Studies on the selective lysis and purification of Trypanosoma cruzi. J Exp Med. 1975 Jul 1;142(1):224–229. doi: 10.1084/jem.142.1.224. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Podack E. R., Tschopp J. Circular polymerization of the ninth component of complement. Ring closure of the tubular complex confers resistance to detergent dissociation and to proteolytic degradation. J Biol Chem. 1982 Dec 25;257(24):15204–15212. [PubMed] [Google Scholar]
  19. Puentes S. M., Sacks D. L., da Silva R. P., Joiner K. A. Complement binding by two developmental stages of Leishmania major promastigotes varying in expression of a surface lipophosphoglycan. J Exp Med. 1988 Mar 1;167(3):887–902. doi: 10.1084/jem.167.3.887. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Ramm L. E., Whitlow M. B., Mayer M. M. Transmembrane channel formation by complement: functional analysis of the number of C5b6, C7, C8, and C9 molecules required for a single channel. Proc Natl Acad Sci U S A. 1982 Aug;79(15):4751–4755. doi: 10.1073/pnas.79.15.4751. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Rimoldi M. T., Sher A., Heiny S., Lituchy A., Hammer C. H., Joiner K. Developmentally regulated expression by Trypanosoma cruzi of molecules that accelerate the decay of complement C3 convertases. Proc Natl Acad Sci U S A. 1988 Jan;85(1):193–197. doi: 10.1073/pnas.85.1.193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Schenkman S., Güther M. L., Yoshida N. Mechanism of resistance to lysis by the alternative complement pathway in Trypanosoma cruzi trypomastigotes: effect of specific monoclonal antibody. J Immunol. 1986 Sep 1;137(5):1623–1628. [PubMed] [Google Scholar]
  23. Schönermark S., Rauterberg E. W., Shin M. L., Löke S., Roelcke D., Hänsch G. M. Homologous species restriction in lysis of human erythrocytes: a membrane-derived protein with C8-binding capacity functions as an inhibitor. J Immunol. 1986 Mar 1;136(5):1772–1776. [PubMed] [Google Scholar]
  24. Zalman L. S., Wood L. M., Müller-Eberhard H. J. Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels. Proc Natl Acad Sci U S A. 1986 Sep;83(18):6975–6979. doi: 10.1073/pnas.83.18.6975. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES